Reported 2 days ago
PTC Therapeutics, Inc. (PTCT) is highlighted as one of billionaire David E. Shaw’s top small-cap stock picks, showcasing significant upside potential, especially backed by its advancements in rare disorder treatments. The company recently reported robust revenue growth, particularly from its Duchenne Muscular Dystrophy treatments, and has plans to launch new products that could substantially increase its revenue. With a market cap of $3.52 billion and an upside potential of 47.21%, PTC stands out in Shaw's well-regarded investment portfolio amid overall market uncertainties.
Source: YAHOO